611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Health Tip: Prevent Respiratory InfectionsThanksgiving Overeating Could Spell Kidney ProblemsResearchers ID Microbiome Genes Tied to AsthmaPlasma Rich in Growth Factors May Promote Hair RegenerationBest Practice Advice Issued for Hep B Vaccination, ScreeningIs a Common Shoulder Surgery Useless?NAFLD Linked to Smaller Total Cerebral Brain VolumeSalivary miRNAs Can ID Duration of Concussion SymptomsHigh Salt Intake Impacts Gut MicrobiomeSevere Psoriasis May Make Diabetes Increasingly LikelyNAFLD Linked to Increased Cancer Incidence RateSpinal Cord Stimulation May Reduce Neuropathic PainBrain Glucose Responses Diminish With Diabetes, ObesityMany Health Care Providers Work While SickIntensive BP Control Lacks Benefit in Chronic Kidney DiseaseGulf War Illness, Chronic Fatigue Syndrome Are Distinct Disorders: Study'Boomers' Doing Better at Avoiding Eye Disease of AgingAHA: Supervised Exercise Ups 6-Minute Walking Distance in PADAccurate Diagnosis Seen With Photographs of Skin ConditionsModel Predicts Development of Chronic Kidney DiseaseNew Hemophilia Treatment Stems Bleeding EpisodesHealth Tip: If There's a Wildfire NearbyPeanut Patch Found Safe, Effective for Treating AllergiesWhy a Headache Feels So DrainingStaying Active May Lower Odds for GlaucomaHow to Do a Skin Cancer Body CheckCan Treating Gum Disease Keep Blood Pressure in Line?AHA/ACA Present New Blood Pressure GuidelinesAAO: Higher Exercise Intensity Tied to Reduced Risk of GlaucomaAAO: Intranasal Tear Neurostimulator Safe for Dry EyeOutcomes for Atrial Fibrillation Similar With Dabigatran, WarfarinOutbreaks Linked to Drinking Water Mainly Due to LegionellaIs Low-Dose Aspirin Right for You After Surgery?Swings in Blood Pressure Can Pose Long-Term DangersAHA: Acetylcysteine, Sodium Bicarbonate Don't Cut Renal RiskBinge-Watchers, Beware: Long TV Time Poses Clot RiskObesity to Blame for Epidemic of Knee Dislocations, ComplicationsThe Heart Risks of a Desk JobCould Fish Oil, Vitamin D Help Ease Lupus?Smog May Harm Your Bones, TooOverlapping Surgery Appears Safe in Neurosurgical ProceduresAdding Exercise to Compression Therapy Promising for Leg UlcersRisk of End-Stage Renal Disease Low With Type 1 DiabetesHealth Tip: What's Healthy Blood Pressure?'Old' Lungs May Be Good Transplant OptionsHPV Vaccine Linked to Drop in Cases of Rare Childhood DiseaseNeurologic Abnormalities Identified After West Nile VirusSodium Oxybate Promising for Parkinson's, Daytime SleepinessDrop in Incidence of End-Stage Renal Disease Due to DiabetesThese Foods May Help Ease Rheumatoid Arthritis Pain
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

FDA OKs Kalydeco for Additional Mutations in Cystic Fibrosis


HealthDay News
Updated: May 18th 2017

new article illustration

THURSDAY, May 18, 2017 (HealthDay News) -- The U.S. Food and Drug Administration says it has expanded approval for the cystic fibrosis medication Kalydeco (ivacaftor) to include 33 mutations of the disease, up from the previous 10 mutations.

In a media release, the agency said its decision was based on results of laboratory testing and previous clinical trials. Kalydeco is available as tablets or oral granules to be taken two times a day with fat-containing food.

Common side effects of the drug include headache, upper respiratory-tract infection, abdominal pain, diarrhea, rash, nausea, and dizziness. St. John's Wort and similar drugs and supplements could diminish Kalydeco's effectiveness and should be avoided, the FDA said.

"Many rare cystic fibrosis mutations have such small patient populations that clinical trial studies are not feasible," Janet Woodcock, M.D., director of the agency's Center for Drug Evaluation and Research, said in a statement. "This challenge led us to using an alternative approach based on precision medicine, which made it possible to identify certain gene mutations that are likely to respond to Kalydeco."

Kalydeco is produced by Boston-based Vertex Pharmaceuticals.

More Information